Evidence for IVIG-mediated complement inhibition and reduced inflammation

IVIG robustly inhibits complement in complement-mediated diseases like dermatomyositis and reduces inflammation across diverse conditions through both complement-dependent and independent mechanisms.

Abstract

IVIG-mediated complement inhibition is demonstrable but disease-specific, occurring robustly in complement-mediated microangiopathies while absent in neuroinflammatory conditions despite therapeutic efficacy. In dermatomyositis, IVIG achieved 70.6-93.4% inhibition of C3 uptake and normalization of SC5b-9 levels, with direct demonstration of C3b NEO and MAC deposit disappearance from endomysial capillaries. A second dermatomyositis cohort confirmed complement attenuation, with C3b2-containing complexes dropping to 37% of baseline. In multifocal motor neuropathy, IVIG decreased complement deposition and reduced C1q, C4, and classical pathway activity. Conversely, in chronic inflammatory demyelinating polyneuropathy, IVIG demonstrated clear therapeutic efficacy without modulating complement activation products (C3a, C5a, sTCC), indicating efficacy through complement-independent mechanisms. Anti-inflammatory effects were documented across multiple conditions through diverse pathways: IVIG profoundly modulated the IL-1 system in primary hypogammaglobulinaemia, selectively reduced proinflammatory cytokines TNF-α and IL-1β in Guillain-Barré syndrome, and produced significant reductions in disease activity scores and inflammatory markers in ANCA-associated vasculitis (BVAS SMD -1.7, CRP SMD -0.92) and systemic lupus erythematosus (SMD 0.584). Clinical effectiveness ranged from 52.7% response in Guillain-Barré syndrome to 75% in dermatomyositis, with improvements correlating with the primary disease mechanism—complement inhibition in complement-mediated diseases and cytokine modulation in others.

Methods

We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. More on methods

Records from Elicit search

n = 200

Papers screened using: Human Subjects, Relevant Outcomes, Study Design, IVIG Preparation, Quantitative Data, IVIG Attribution, Publication Quality

n = 200

Papers screened out

n = 190

Papers included for extraction

n = 10

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

We ran this query: “Evidence for IVIG-mediated complement inhibition and reduced inflammation”

The search returned 200 total results from Elicit.

We retrieved 200 papers most relevant to the query for screening.

Screening

We screened in sources based on their abstracts that met these criteria:

• Human Subjects: Does this study investigate IVIG therapy in human subjects (not exclusively in vitro or animal studies)?
• Relevant Outcomes: Does this study measure complement system activity/components (C3, C4, C5, CH50, alternative pathway markers, etc.) OR inflammatory markers (CRP, ESR, cytokines, clinical inflammation scores)?
• Study Design: Is this study a randomized controlled trial, cohort study, case-control study, case series with ≥5 patients, systematic review, or meta-analysis?
• IVIG Preparation: Does this study use standard IVIG preparations (excluding hyperimmune globulins, subcutaneous preparations, or experimental formulations)?
• Quantitative Data: Does this study report quantitative data on complement or inflammatory outcomes?
• IVIG Attribution: Can the effects of IVIG be isolated in this study (i.e., not combination therapies without control groups or baseline measurements that would prevent attributing effects to IVIG)?
• Publication Quality: Is this a full-text peer-reviewed publication (not a conference abstract, letter, editorial, opinion piece, or case report/series with <5 patients)?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

• Study Context: Extract the disease condition being studied and basic study design (RCT, observational, case series, etc.). Focus on conditions where IVIG-mediated complement inhibition and/or anti-inflammatory effects are being investigated.
• IVIG Protocol: Extract IVIG intervention details relevant to complement and inflammatory mechanisms, including:
  • Dose (g/kg)
  • Frequency and duration of treatment
  • Time points when complement/inflammatory markers were measured relative to IVIG administration
  • Any comparison groups (placebo, other treatments, untreated controls)
• Complement Inhibition Evidence: Extract all evidence for IVIG-mediated complement inhibition, including:
  • Specific complement components/products measured (C3, C3a, C5a, MAC/SC5b-9, C3b deposits, etc.)
  • Baseline complement levels/activity
  • Changes in complement levels/activity after IVIG treatment
  • Methods used to assess complement (serum assays, tissue staining, functional assays)
  • Time course of complement changes
  • Whether complement inhibition was directly demonstrated or inferred
  • Any evidence against complement inhibition
• Inflammation Reduction Evidence: Extract all evidence for IVIG-mediated anti-inflammatory effects, including:
  • Specific inflammatory markers measured (cytokines like TNF-α, IL-1β, IL-6; acute phase reactants like CRP, ESR; disease activity scores; other inflammatory indicators)
  • Baseline inflammatory marker levels
  • Changes in inflammatory markers after IVIG treatment
  • Time course of anti-inflammatory effects
  • Whether effects were on pro-inflammatory vs anti-inflammatory mediators
  • Clinical manifestations of reduced inflammation
• Mechanistic Relationships: Extract evidence linking complement inhibition to reduced inflammation in IVIG-treated patients, including:
  • Whether the study explicitly examined relationships between complement and inflammatory changes
  • Temporal relationships (which occurred first)
  • Correlations between complement inhibition and inflammation reduction
  • Proposed mechanisms connecting complement inhibition to anti-inflammatory effects
  • Evidence for or against complement-independent anti-inflammatory mechanisms
• Clinical Outcomes: Extract clinical effectiveness measures to determine if complement inhibition and/or inflammation reduction translate to patient benefit, including:
  • Disease-specific activity/severity scores
  • Functional improvement measures
  • Time to improvement
  • Duration of benefit
  • Correlation between biochemical changes (complement/inflammation) and clinical improvement
  • Response rates and effect sizes where available

Results

Characteristics of included studies

The review encompassed 10 sources examining IVIG effects across diverse autoimmune and inflammatory conditions. Three sources were double-blind placebo-controlled trials, two were systematic reviews with meta-analysis, one was a clinical trial, and four were observational studies or case series. The conditions studied included dermatomyositis, multifocal motor neuropathy, systemic lupus erythematosus, chronic inflammatory demyelinating polyneuropathy, primary hypogammaglobulinaemia, Guillain-Barré syndrome, and ANCA-associated vasculitis.

Evidence for complement inhibition

Three studies provided direct evidence of IVIG-mediated complement inhibition, while one study explicitly demonstrated absence of such effects. The mechanisms, time courses, and magnitude of effects varied substantially across conditions.

In dermatomyositis, IVIG produced robust complement inhibition. Post-IVIG sera inhibited C3 uptake by 70.6-93.4% without depleting complement components. The mechanism involved formation of complexes between infused immunoglobulins and C3b, preventing incorporation of activated C3 molecules into C5 convertase. Maximum inhibition occurred within hours after infusion, began rebounding after 2 days, and returned to pretreatment levels by 30 days. In muscle biopsies from improved patients, C3b NEO and MAC deposits disappeared from endomysial capillaries with restoration of the capillary network.

In multifocal motor neuropathy, IVIG decreased complement deposition by anti-GM1 IgM antibodies in vitro. First treatment (2 g/kg) decreased C1q and C4 concentrations and classical pathway activity in serum. During maintenance therapy (0.4 g/kg), C4 concentrations and classical pathway activity were generally lower at higher IgG concentrations.

Conversely, CIDP patients showed no complement modulation despite IVIG efficacy. Serum levels of C3a, C5a, and sTCC were not modulated by IVIG and remained unchanged in patients with beneficial responses compared to those with steady or worsened disease.

Evidence for anti-inflammatory effects

Anti-inflammatory effects of IVIG were documented across multiple conditions through diverse markers including proinflammatory cytokines, acute phase reactants, and disease activity scores.

In primary hypogammaglobulinaemia, IVIG produced profound modulation of the IL-1 system. Patients had significantly elevated baseline levels of IL-1α and IL-1β compared to healthy controls. After one bolus infusion (0.4 g/kg), IL-1Ra levels increased markedly along with neutralizing antibodies against IL-1α. Concurrently, IL-1α and IL-1β levels decreased moderately, sIL-1 receptor type I decreased moderately, and sIL-1 receptor type II levels increased significantly.

In Guillain-Barré syndrome, circulating levels of TNF-α and IL-1β decreased after IVIG treatment but remained relatively high in untreated patients and those treated by plasma exchange. Clinical improvement in IVIG-treated patients was associated with reduction in unbound TNF-α during the acute phase.

In ANCA-associated vasculitis, meta-analysis demonstrated significant reductions in disease activity and inflammatory markers within 6 months of IVIG administration. BVAS decreased with a standardized mean difference of -1.7, ANCA levels decreased, and CRP decreased.

Clinical effectiveness

Clinical effectiveness varied across conditions, with stronger evidence in complement-mediated diseases and robust functional improvements in several studies. In dermatomyositis, IVIG produced rapid and substantial clinical benefits. In the placebo-controlled trial, MRC scores increased from 74.5 to 84.7 and neuromuscular symptom scores increased from 38.6 to 51.0. Improvement occurred within hours after IVIG infusion, with functional gains including increased muscle strength and resolution of muscle ischemia. The clinical improvement correlated directly with C3 uptake inhibition.

In Guillain-Barré syndrome, 52.7% of patients receiving IVIG showed functional improvement of one grade or more after 4 weeks. In ANCA-associated vasculitis, IVIG produced rapid improvements, with significant reductions in BVAS, ANCA, and CRP occurring within 6 months.

The duration of benefit varied substantially. In dermatomyositis, C3 uptake inhibition rebounded to pretreatment levels after 30 days, necessitating repeated infusions for sustained clinical benefit.